Nivolumab/Ipilimumab Continues to Show Survival Benefit in Melanoma

Source: Cancer Network, January 2025

The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) or nivolumab monotherapy demonstrated a continued, ongoing survival benefit when compared with ipilimumab monotherapy, in patients with advanced melanoma, according to the randomized, double-blind phase 3 CheckMate 067 trial (NCT01844505) published in The New England Journal of Medicine.

At a median follow-up of 10 years, patients who received nivolumab plus ipilimumab experienced a median overall survival (OS) of 71.9 months (95% CI, 38.2-114.4), patients who received nivolumab monotherapy had a median OS of 36.9 months (95% CI, 28.2-58.7), and patients who received ipilimumab had a median OS of 19.9 months (95% CI, 16.8-24.6). The HR for death for nivolumab plus ipilimumab vs ipilimumab monotherapy was 0.53 (95% CI, 0.44-0.65) and the HR for nivolumab monotherapy vs ipilimumab monotherapy was 0.63 (95% CI, 0.52-0.76).
READ THE ORIGINAL
FULL ARTICLE